Shukra Pharmaceuticals Ltd. has formally notified BSE Limited about an upcoming board meeting scheduled for May 7, 2026, at the company's registered office. The intimation, filed on April 29, 2026, complies with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Agenda Items

The board meeting will address several critical corporate matters for the pharmaceutical company:

Regulatory Compliance

The meeting intimation demonstrates the company's adherence to SEBI regulations, particularly Regulation 33 concerning the disclosure of financial results. The board will consider audited financial statements along with the auditor's report and certificate for unmodified opinion, ensuring transparency in financial reporting.

Dividend Consideration

Shareholders will be particularly interested in the board's recommendation for a final dividend for the financial year 2025-26. This decision will depend on the company's financial performance and cash flow position as reflected in the audited results.

Corporate Governance

The formal intimation was signed by Ritu Kapoor, Director with DIN: 10334249, reflecting proper corporate governance protocols. The company maintains its registration under CIN: L24231GJ1993PLC019079, indicating its established presence in the pharmaceutical sector since 1993.

Shukra Pharmaceuticals Limited has filed its quarterly compliance certificate with BSE Limited, fulfilling regulatory requirements under SEBI depositories regulations for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The pharmaceutical company submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 on April 8, 2026. The filing was made through the company's Corporate Relationship Department to BSE Limited's General Manager-Listing department.

Registrar and Transfer Agent Confirmation

Purva Sharegistry (India) Private Limited, serving as the company's Registrar and Transfer Agent, issued the confirmation certificate dated April 1, 2026. The certificate confirms compliance with SEBI regulations regarding dematerialisation processes and stock exchange listing requirements.

The registrar confirmed that securities received from depository participants for dematerialisation during the quarter were processed according to prescribed timelines and regulatory guidelines. Ms. Deepali Gaonkar, Compliance Officer at Purva Sharegistry, signed the confirmation certificate.

Dematerialisation Activity

The detailed report for the quarter from January 1, 2026 to March 31, 2026 shows no dematerialisation activity during this period.

Corporate Information

Shukra Pharmaceuticals Limited operates under CIN L24231GJ1993PLC019079, indicating its incorporation in Gujarat in 1993. The company maintains its regulatory compliance through systematic quarterly filings with stock exchanges and depositories as required under SEBI regulations.